Type B lactic acidosis: A rare complication of antiretroviral therapy after cardiac surgery

Annals of Thoracic Surgery

Volumn 74, Issue 4, 2002, Pages 1251-1252

  Vasseur, Bernard G ^a,b   Kawanishi, Hideki ^b   Shah, Nahir ^c   Anderson, Mark L ^a  

^a Department of Emergency Medicine   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c SAINT PETER S UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RIBOFLAVIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THIAMINE; VANCOMYCIN;

ADULT; ALLOGRAFT; AORTA ROOT; CASE REPORT; CLINICAL FEATURE; CONFERENCE PAPER; CONVALESCENCE; DISEASE COURSE; DRUG WITHDRAWAL; ENDOCARDITIS; FEMALE; HEMODIALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; LACTIC ACIDOSIS; LACTIC ACIDOSIS TYPE B; OPEN HEART SURGERY; PRIORITY JOURNAL; RISK FACTOR; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

ACIDOSIS, LACTIC; ANTI-HIV AGENTS; AORTIC VALVE; FEMALE; HEART VALVE PROSTHESIS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; KIDNEY FAILURE, CHRONIC; LAMIVUDINE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RENAL DIALYSIS; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; STAVUDINE;

EID: 0036796230     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(02)03887-0     Document Type: Conference Paper

References (12)

1. Ritz E, Heidland A. Lactic acidosis. Clin Nephrol 1977;7:231-40.
2. Raper R, Cameron G, Walker D, Bowey CJ. Type B lactic acidosis following cardiopulmonary bypass. Crit Care Med 1997;25:46-51.
3. Chiolero RL, Revelly JP, Leverve X, et al. Effects of cardiogenic shock on lactate and glucose metabolism after heart surgery. Crit Care Med 2000;28:3784-91.
4. Mokrzycki MH, Harris C, May H, Laut J, Palmisano J. Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis 2000;30:198-200.
5. Megarbane B, Brivet F, Guerin JM, Baud FJ. Lactic acidosis and multi-organ failure secondary to anti-retroviral therapy in HIV-infected patients. Presse Med 1999;28:2257-64.
6. Walker UA, Venhoff N. Multiple mitrochondrial DNA deletions and lactic acidosis in an HIV-infected patient under antiretroviral therapy [letter]. AIDS 2001;15:1449-50.
7. Woods ML, Barley PB. Response to multiple mitochondrial DNA deletions and lactic acidosis in an HIV-infected patient under antiretroviral therapy [letter]. AIDS 2001;15:1450.
8. Walker UA, Venhoff N. An argument for mitochondrial toxicity in highly active antiretroviral therapy-induced lipoatrophy [letter]. AIDS 2001;15:1450-2.
9. Brinkman K, Hofstedeter HJM, Burger DM, Smeitink J, Koopmans PP. Adverse effects of reverse transcriptase inhibitors mitochondrial toxicity as common pathway. AIDS 1998;12:1735-44.
10. Chodock R, Mylonakis E, Shemin D, et al. Survival of a human immunodeficiency patient with nucleoside-induced lactic acidosis-role of haemodiayslis treatment. Nephrol Dial Transplant 1999;14:2884-6.
11. Miller K, Cameron M, Wood L, Dalakas M, Kovac J. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000;133:192-6.
12. Fouty B, Frerman F, Reves R. Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet 1998;352:291-2.